Medical News Today: What to know about proton therapy for breast cancer

This article discusses its uses, effectiveness, and procedure.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news

Related Links:

To investigate the role of intensity-modulated proton therapy (IMPT) for regional nodal irradiation in patients with breast carcinoma in comparison with volumetric-modulated arc therapy (VMAT).
Source: Clinical Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
CONCLUSION: If MC is more accurate than PB as reported in the literature, dosimetric and radiobiological results from the current study suggest that PB overestimates the target dose, EUD, and TCP for IMPT breast cancer treatment. The overestimation of dosimetric and radiobiological results of the target volume by PB needs to be further interpreted in terms of clinical outcome. PMID: 31343826 [PubMed - as supplied by publisher]
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
CONCLUSIONS: IMPT following IBR spared underlying organs and had low rates of acute toxicity. Reconstruction complications are more common in irradiated breasts, and reconstructive outcomes appear comparable with photon literature. Hypofractionation was associated with higher reconstruction failure rates. Further investigation of optimal dose-fractionation after IBR is needed. PMID: 31185327 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
University of Cincinnati researchers plan to enroll more than 20 women with early stage breast cancer in a unique clinical trial, which will involve the most expensive medical device in the region. The trial will involve proton radiotherapy designed to zap cancer with particles that travel faster than a bolt of lightning – and with great precision.  Treatment will take place at the $120 million Cincinnati Children’s Hospital Medical Center/UC Health Proton Therapy Center in Butler Coun ty,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
University of Cincinnati researchers plan to enroll more than 20 women with early stage breast cancer in a unique clinical trial, which will involve the most expensive medical device in the region. The trial will involve proton radiotherapy designed to zap cancer with particles that travel faster than a bolt of lightning – and with great precision.  Treatment will take place at the $120 million Cincinnati Children’s Hospital Medical Center/UC Health Proton Therapy Center in Butler Coun ty,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Current proton therapy clinical practices primarily use the pencil-beam (PB) algorithm for dose calculations, as it has been the mainstay of commercially-available proton dose calculation algorithms and offers efficient treatment planning workflow. On the other hand, PB algorithms are known to be inaccurate in heterogeneous tissue environment or when a range shifter is used. To this end, Monte Carlo (MC) algorithm have recently been introduced into proton treatment planning systems that provide much more accurate dose modeling.
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
In this study, we evaluate the potential reduction in radiation-induced skin morbidity obtained by intensity modulated proton therapy (IMPT) compared with intensity modulated photon therapy (IMXT) for left-side BC and RNI. MATERIAL AND METHODS: Using CT scans from 10 left-side BC patients, treatment plans were generated using IMXT and IMPT techniques. A dose of 50 Gy (or Gy [RBE] for IMPT) was prescribed to the target volume (involved breast, the internal mammary, supraclavicular, and infraclavicular nodes). Two single filed optimization IMPT (IMPT1 and IMPT2) plans were calculated without and with skin optimiz...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Mudit Chowdhary, Anna Lee, Sarah Gao, Dian Wang, Parul N. Barry, Roberto Diaz, Neeti R. Bagadiya, Henry S. Park, James B. Yu, Lynn D. Wilson, Meena S. Moran, Susan A. Higgins, Christin A. Knowlton, Kirtesh R. Patel
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Early stage medical equipment developer EhmetDX said late last week that it won FDA 510(k) clearance for its 3D CBCT positioning software. The Plymouth, Mich.-based company said that the newly cleared system is designed to guide the position of proton beams in patient treatments. The system is slated to be used in patient treatment at the McLaren Proton Therapy Center beginning this month, EhmetDx said. “We look forward toward patient treatment using our software for positioning now that the FDA concluded that our X-ray positioning system has met the requirements needed for 510(k).  With patient treatment immine...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Regulatory/Compliance ehmetdx Source Type: news
CONCLUSIONS: The obtained results are encouraging for the future of Raman spectroscopy in radiobiology research, particularly for improving risk assessment in the field of proton radiotherapy. Specifically, these findings validate Raman spectroscopy to measure biological response in human breast cells exposed to standard proton therapy doses used in clinical setting. PMID: 30496011 [PubMed - as supplied by publisher]
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Proton Therapy